Cadrenal Therapeutics, Inc. current report, 20 October 2023

Full document

Cadrenal Therapeutics, Inc. Form 8-K Summary

Business Context and Reporting Period

Cadrenal Therapeutics, Inc. filed a Current Report on Form 8-K regarding its 2023 Annual Meeting of Stockholders held on October 20, 2023. The company is incorporated in Delaware, trades on Nasdaq under the symbol CVKD, and is an emerging growth company.

Financial and Operating Metrics

This filing does not provide revenue, profit, cash flow, margins, debt, liquidity, or other financial performance metrics.

Material Changes and Voting Results

  • Quang Pham was elected as a Class I director to serve until the 2026 Annual Meeting or until a successor is elected and qualified: 10,183,242 votes for, 8,560 withheld, and 945,722 broker non-votes.
  • Glynn Wilson was elected as a Class I director to serve until the 2026 Annual Meeting or until a successor is elected and qualified: 10,139,612 votes for, 52,190 withheld, and 945,722 broker non-votes.
  • Stockholders ratified WithumSmith+Brown, P.C. as the company’s independent registered public accounting firm for the year ending December 31, 2023: 11,126,433 votes for, 10,899 against, 192 abstentions, and no broker non-votes.
  • As of the August 25, 2023 record date, 13,022,754 shares were entitled to vote. More than 34% of voting shares were represented, constituting a quorum.

Guidance, Outlook, Risks, and Unusual Items

The filing contains no financial guidance, operational outlook, new risk disclosures, contingencies, or unusual financial items. It reports corporate governance actions and auditor ratification only.

Key Investor Verification Items

  • Verify the elected director terms and the company’s current board composition.
  • Verify the appointment of WithumSmith+Brown, P.C. for the year ending December 31, 2023.
  • Review the company’s separate periodic filings for financial results, cash position, financing needs, liquidity risks, and clinical or development updates, none of which are provided in this 8-K.
  • Confirm the voting totals against the company’s definitive proxy statement filed August 28, 2023.